Pfizer Inc. / NextWave Pharmaceuticals, Inc.

Attention-Deficit/Hyperactivity Disorder (ADHD)

$14.3B Global ADHD market 2023 (~69% US share)

Disease Overview

ADHD is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity that impairs academic, occupational, and social functioning. It affects ~11% of US children and ~4% of adults, with stimulant medications (methylphenidate and amphetamine derivatives) the first-line pharmacotherapy. The pediatric segment in particular has long needed liquid or chewable formulations for younger children and patients unable to swallow pills.

Competitive Landscape

The 2012 US ADHD market was dominated by Shire's Vyvanse (lisdexamfetamine) and Adderall XR (mixed amphetamine salts), Janssen's Concerta (methylphenidate OROS), Novartis's Ritalin/Focalin franchise, and Shire's non-stimulant Intuniv — collectively a multi-billion-dollar branded market with active generic erosion on older methylphenidate ER products. Long-acting once-daily methylphenidate ER tablets/capsules (Concerta, Metadate CD, Ritalin LA) covered most pediatric prescribing, but no extended-release liquid existed before Quillivant XR — leaving a gap for younger children, patients with swallowing difficulty, and parents who needed dose flexibility. Quillivant XR (NextWave/Tris Pharma's OralXR+ platform, FDA approved Sept 27, 2012) was the first once-daily liquid methylphenidate. For Pfizer, the deal was an ADHD market entry — it had no prior ADHD asset — using its established-products commercial infrastructure to launch into a Shire-dominated category. The ~$680-700M deal value (with $425M of it back-loaded as sales milestones) reflected Pfizer's confidence in differentiation but limited willingness to underwrite branded-stimulant peak-share risk against entrenched competitors. Quillivant XR ultimately reached ~$193M gross sales by 2017.